Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Noiiglutide

Stage Phase 3Stale

Sponsor Jiangsu HengRui Medicine Co., Ltd.

Route oral and injection

Sources

registry, as of 2022-03-15Stale

https://clinicaltrials.gov/study/NCT06649773

The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 137. Conditions Type 2 Diabetes. This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.

ClinicalTrials.gov NCT06649773 protocol and results modules

registry, as of 2022-11-07Stale

https://clinicaltrials.gov/study/NCT03848793

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 128. Conditions Diabetes Mellitus, Type 2. The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.

ClinicalTrials.gov NCT03848793 protocol and results modules

registry, as of 2022-03-15Stale

https://clinicaltrials.gov/study/NCT04799327

The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without Diabetes. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 254. Conditions Obesity. The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes.

ClinicalTrials.gov NCT04799327 protocol and results modules

Studies

The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients

Registry NCT06649773

Phase Phase 3

Status Completed

Enrollment 137

Start 2024-11-06

Primary completion 2025-05-28

Study completion 2025-12-11

Catalyst Primary completion. 2025-05-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Noiiglutide Injection

Comparator placebo

Population Type 2 Diabetes

Noiiglutide Placebo

Population Type 2 Diabetes

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Registry NCT03848793

Phase Phase 2

Status Completed

Enrollment 128

Start 2019-03-06

Primary completion 2020-06-04

Study completion 2020-12-14

HS-20004 or placebo treatment (Low dose)

Regimen once daily

Weeks 16

Population Diabetes Mellitus, Type 2

HS-20004 or placebo treatment (median dose 1)

Regimen once daily

Weeks 16

Population Diabetes Mellitus, Type 2

HS-20004 or placebo treatment (median dose 2)

Regimen once daily

Weeks 16

Population Diabetes Mellitus, Type 2

HS-20004 or placebo treatment (high dose)

Regimen once daily

Weeks 16

Population Diabetes Mellitus, Type 2

The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without Diabetes

Registry NCT04799327

Phase Phase 2

Enrollment 254

Start 2021-03-29

Primary completion 2022-05-15

Study completion 2022-05-15

Treatment group A

Comparator placebo

Population Obesity

Treatment group B

Comparator placebo

Population Obesity

Treatment group C

Comparator placebo

Population Obesity

Treatment group D

Population Obesity